Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PANRETIN vs AVAGE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Alitretinoin is a naturally occurring endogenous retinoid that binds to and activates all known intracellular retinoid receptors (RARα, RARβ, RARγ, RXRα, RXRβ, RXRγ). It modulates cell growth, differentiation, and apoptosis in both normal and malignant cells. In Kaposi sarcoma, it inhibits tumor cell proliferation and induces differentiation.
Avage (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RAR-β, RAR-γ) with high affinity and modulates gene expression, leading to reduced keratinocyte proliferation, differentiation, and inflammation.
FDA-approved: Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi sarcoma,Off-label: Treatment of chronic hand eczema (oral formulation, not available in US)
FDA-approved for the topical treatment of stable plaque psoriasis (up to 20% body surface area),FDA-approved for the topical treatment of mild to moderate acne vulgaris,Off-label: treatment of photoaging, facial wrinkles, and certain hyperpigmentation disorders
Apply 0.1% gel topically to lesions twice daily.
Applied topically as a cream 0.05% to affected areas once daily at bedtime.
Mean terminal half-life of approximately 5-10 hours; clinical context: supports twice-daily topical application.
Terminal elimination half-life is approximately 2-4 hours in patients with normal renal function; prolonged to 12-24 hours in severe renal impairment (Cr Cl <30 m L/min).
Metabolized primarily by CYP2C9, CYP3A4, and CYP2C8 to major metabolites (e.g., 4-oxo-alitretinoin, 9-cis-retinoic acid). Glucuronidation also contributes.
Tazarotene is rapidly metabolized via ester hydrolysis to its active metabolite, tazarotenic acid. Tazarotenic acid is further metabolized via oxidation and conjugation (glucuronidation). The enzymes involved include esterases and possibly CYP450 isoforms; specific CYP450 enzymes are not well characterized.
Primarily hepatic metabolism; less than 1% excreted unchanged in urine.
Primarily renal excretion (70-80% as unchanged drug) with 10-20% biliary/fecal elimination.
>99% bound to plasma proteins, primarily albumin and lipoproteins.
Approximately 90% bound to albumin and alpha-1-acid glycoprotein.
Not applicable for topical administration; systemic absorption is minimal with no established Vd.
0.3-0.5 L/kg, indicating distribution primarily into extracellular fluid.
Systemic bioavailability after topical application is <1% of applied dose.
Oral: 60-70% due to first-pass metabolism; Intravenous: 100%.
No dose adjustment required for renal impairment.
No specific dose adjustment required for renal impairment.
No dose adjustment recommended for hepatic impairment.
No specific dose adjustment required for hepatic impairment.
Not indicated for pediatric patients below 18 years of age.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
No specific dose adjustment; use with caution due to potential for increased skin sensitivity.
No specific dose adjustment required; however, use with caution due to potential increased sensitivity and skin fragility in elderly patients.
Not applicable for topical formulation. Oral alitretinoin (not marketed in US) carries a boxed warning for teratogenicity and must not be used during pregnancy.
Avage is contraindicated in women who are or may become pregnant. Tazarotene is a teratogen, and fetal harm can occur when administered to a pregnant woman. If the drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
Teratogenicity: Avoid use during pregnancy; effective contraception required,Photosensitivity: Avoid excessive sun exposure,Local skin reactions: erythema, edema, peeling at application site,Hyperlipidemia: Monitor lipids in prolonged use,Pancreatitis: Risk in patients with hypertriglyceridemia,Hepatotoxicity: Monitor liver function tests,Pseudotumor cerebri: Discontinue if signs of intracranial hypertension
Avoid contact with eyes, mouth, and mucous membranes,Not for use on eczematous or sunburned skin,May cause severe local skin reactions (e.g., redness, peeling, burning, stinging),Photosensitivity: patients should avoid or minimize exposure to sunlight and artificial UV sources,Concomitant use with other photosensitizing agents should be approached with caution
Hypersensitivity to alitretinoin or any component of the formulation,Pregnancy (topical: use only if no safer alternative; oral: absolutely contraindicated)
Pregnancy (FDA Pregnancy Category X),Women of childbearing potential unless using effective contraception and have a negative pregnancy test within 2 weeks prior to therapy,Hypersensitivity to tazarotene or any component of the formulation
No known food interactions. Avoid concurrent use of other topical products on the same area.
AVAGE should be taken with a meal containing fat (e.g., whole milk, peanut butter) to enhance absorption. Avoid excessive vitamin A supplements as they may add to toxic effects. Grapefruit juice may increase isotretinoin levels; consider avoidance.
PANRETIN (alitretinoin) is a retinoid and is contraindicated in pregnancy. Category X: Animal studies have demonstrated teratogenic effects (craniofacial, cardiovascular, CNS abnormalities). First trimester exposure carries highest risk. Second and third trimester: risk of fetal retinoid syndrome (craniofacial dysmorphism, CNS anomalies, cardiovascular malformations). Effective contraception must be used.
FDA Pregnancy Category X. First trimester: High risk of major congenital malformations including craniofacial defects (cleft lip/palate), cardiovascular abnormalities, and neural tube defects. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and premature closure of the ductus arteriosus. Avoid use throughout pregnancy.
No data on excretion in human milk. Retinoids are known to be excreted in animal milk. Because of potential for serious adverse reactions in nursing infants (teratogenicity, retinoid toxicity), breastfeeding is contraindicated during therapy and for at least 1 month after last dose.
Contraindicated in breastfeeding. Excreted into human milk; M/P ratio not established. Risk of serious adverse effects in nursing infant, including keratoderma-like skin changes and potential for growth impairment.
Contraindicated in pregnancy; no dose adjustments applicable. Ensure patient is not pregnant before initiating therapy.
No dose adjustment applicable; drug is absolutely contraindicated in pregnancy due to teratogenicity. No data on pharmacokinetic changes; theoretical increased clearance due to expanded plasma volume may occur but is clinically irrelevant given contraindication.
Panretin (alitretinoin) gel is a topical retinoid indicated for cutaneous Kaposi sarcoma. Use gloves during application; avoid application to normal skin as it may cause irritation. Monitor for local adverse reactions like erythema, edema, and pain. Do not use concurrently with other topical agents on the same site.
AVAGE (isotretinoin) is highly teratogenic; confirm negative pregnancy test within 5 days before starting therapy and monthly thereafter. Monitor triglycerides, liver function, and CBC at baseline and monthly. Avoid blood donation during treatment and for 1 month after discontinuation. Use with caution in patients with depression; monitor for mood changes. Administer with food to increase absorption.
Apply a thin layer only to Kaposi sarcoma lesions, avoiding healthy skin.,Wash hands thoroughly before and after application.,Do not cover with bandages or dressings unless instructed.,Expected side effects include redness, swelling, and pain at application site.,Avoid exposure to sunlight or tanning lamps; use sunscreen on treated areas.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
AVAGE can cause severe birth defects; females must use two effective forms of contraception and have monthly pregnancy tests.,Do not donate blood while taking AVAGE and for 1 month after stopping.,Avoid exposure to sunlight or tanning beds; use sunscreen and protective clothing.,Report any signs of depression, mood changes, or thoughts of self-harm immediately.,Take each dose with a full meal to ensure proper absorption.,May cause dry skin, lips, eyes; use moisturizers and artificial tears as needed.,Avoid waxing or laser treatments during therapy and for 6 months after.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PANRETIN vs AVAGE, answered by our medical review team.
PANRETIN is a Topical Retinoid that works by Alitretinoin is a naturally occurring endogenous retinoid that binds to and activates all known intracellular retinoid receptors (RARα, RARβ, RARγ, RXRα, RXRβ, RXRγ). It modulates cell growth, differentiation, and apoptosis in both normal and malignant cells. In Kaposi sarcoma, it inhibits tumor cell proliferation and induces differentiation.. AVAGE is a Topical Retinoid that works by Avage (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RAR-β, RAR-γ) with high affinity and modulates gene expression, leading to reduced keratinocyte proliferation, differentiation, and inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PANRETIN and AVAGE depend on the specific clinical indication. These are both Topical Retinoid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PANRETIN is: Apply 0.1% gel topically to lesions twice daily.. The standard adult dose of AVAGE is: Applied topically as a cream 0.05% to affected areas once daily at bedtime.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PANRETIN and AVAGE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PANRETIN is classified as Category C. PANRETIN (alitretinoin) is a retinoid and is contraindicated in pregnancy. Category X: Animal studies have demonstrated teratogenic effects (craniofacial, cardiovascular, CNS abnor. AVAGE is classified as Category C. FDA Pregnancy Category X. First trimester: High risk of major congenital malformations including craniofacial defects (cleft lip/palate), cardiovascular abnormalities, and neural t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.